Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumLoretta J. Nastoupil, Frederick L. Locke, André Goy et al.|Journal of Clinical Oncology|2020Cited by 782
Induction of GADD45 and JNK/SAPK-Dependent Apoptosis following Inducible Expression of BRCA1D. Paul Harkin, Daniel A. Haber, James Bean et al.|Cell|1999Cited by 559
Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal StudyRachel Cusatis, Surbhi Sidana, Irena Tan et al.|Blood|2021Cited by 19
CT-305: Optimizing Post-Chimeric Antigen Receptor (CAR) T-Cell Monitoring: Evidence Across Lisocabtagene Maraleucel (liso-cel) Pivotal Clinical Trials and Real-World ExperienceManali Kamdar, Matthew A. Lunning, Mazyar Shadman et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 1
Optimizing post–chimeric antigen receptor (CAR) T cell monitoring: Evidence across lisocabtagene maraleucel (liso-cel) pivotal clinical trials and real-world experience.M. Kamdar, Matthew A. Lunning, Mazyar Shadman et al.|Journal of Clinical Oncology|2025Cited by 0